Linear low-dose extrapolation for noncancer health effects is the exception, not the rule

Lorenz R. RhombergGradient, Cambridge, Massachusetts, USACorrespondence[email protected]

Julie E. GoodmanGradient, Cambridge, Massachusetts, USA

Lynne T. HaberToxicology Excellence for Risk Assessment (TERA), Cincinnati, Ohio, USA

Michael DoursonToxicology Excellence for Risk Assessment (TERA), Cincinnati, Ohio, USA

Melvin E. AndersenThe Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina, USA

James E. KlaunigDepartment of Environmental Health, Indiana University, Bloomington, Indiana, USA

Bette MeekInstitute of Population Health, University of Ottawa, Ottawa, Ontario, Canada

Paul S. PriceThe Dow Chemical Company, Midland, Michigan, USA

Roger O. McClellanAdvisor, Toxicology and Human Health Risk Analysis, Albuquerque, New Mexico, USA

Samuel M. CohenDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, USA

Your download is now in progress and you may close this window